Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers-Reference-Cited by-同舟云学术

Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers

Published:2001-03 Issue:2 Volume:51 Page:153-157
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Dugger H.A.,Carlson J.D.,Henderson William,Erdmann G.R.,Alam S.Mahmood,Dham Ruwayda,Quamruzaman

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference25 articles.

1. A distribution-free procedure for the statistical analysis of bioequivalence studies;Hauschke;Int. J. Clin. Pharmacol. Ther. Toxicol.,1990

2. Striving for standards in bioequivalence assessment: a review;Schulz;Int. J. Clin. Pharmacol. Ther. Toxicol.,1992

3. Index Nominum: International Drug Directory,2000

4. Possible mechanism for the inhibition of gastric (H+,K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749;Nagaya;J. Pharmacol. Exp. Ther.,1989

5. Effects of AG-1749 (lansoprazole) and its metabolites on acid secretion and experimental ulcers (in Japanese);Inatomi;Yakuri to Chiryo,1991

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamics and Pharmacokinetics of a New Type of Compound Lansoprazole Capsule in Gastric Ulcer Rats and Beagle Dogs: Importance of Adjusting Oxidative Stress and Inflammation;Pharmaceutics;2019-01-22

2. Investigation of the bioequivalence of two lansoprazole formulations in healthy Chinese volunteers after a single oral administration;Artificial Cells, Nanomedicine, and Biotechnology;2016-10-31

3. Eudragit L/HPMCAS Blend Enteric-Coated Lansoprazole Pellets: Enhanced Drug Stability and Oral Bioavailability;AAPS PharmSciTech;2014-03-05

4. Prediction of Inter-individual Variability in the Pharmacokinetics of CYP2C19 Substrates in Humans;Drug Metabolism and Pharmacokinetics;2014

5. Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme;Molecules;2012-03-15